New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin 2 mg/ml (equates to ciprofloxacin lactate 2.54 mg/ml in the final formulation) - solution for infusion - 2 mg/ml - active: ciprofloxacin 2 mg/ml (equates to ciprofloxacin lactate 2.54 mg/ml in the final formulation) excipient: hydrochloric acid lactic acid sodium chloride water for injection - infections of the lower respiratory tract. in the treatment of outpatients with pneumonia due to pneumococcus, ciprofloxacin should not be used as a medicine of first choice. ciprofloxacin can be regarded as a suitable treatment for pneumonias caused by klebsiella, enterobacter, proteus, e. coli, pseudomonas, haemophilus, branhamella, legionella, and staphylococcus.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

bayer new zealand limited - estradiol hemihydrate 7.84mg equivalent to estradiol 7.59 mg (100 µg/24h) - transdermal patch - 100 mcg/24h - active: estradiol hemihydrate 7.84mg equivalent to estradiol 7.59 mg (100 µg/24h) excipient: acrylates copolymer ethyl oleate glyceryl monolaurate isopropyl myristate - for short-term treatment of complaints associated with the menopause and post-menopause, including signs and symptoms of oestrogen deficiency, whether naturally or surgically induced. oestrogen replacement therapy in women with an intact uterus should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals. prevention of postmenopausal osteoporosis.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

bayer new zealand limited - estradiol hemihydrate 2.04mg equivalent to estradiol 1.97 mg (25 µg/24h) - transdermal patch - 25 mcg/24h - active: estradiol hemihydrate 2.04mg equivalent to estradiol 1.97 mg (25 µg/24h) excipient: acrylates copolymer ethyl oleate glyceryl monolaurate isopropyl myristate - for short-term treatment of complaints associated with the menopause and post-menopause, including signs and symptoms of oestrogen deficiency, whether naturally or surgically induced. oestrogen replacement therapy in women with an intact uterus should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals. prevention of postmenopausal osteoporosis.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

bayer new zealand limited - estradiol hemihydrate 3.92mg equivalent to estradiol 3.79 mg (50 µg/24h) - transdermal patch - 50 mcg/24h - active: estradiol hemihydrate 3.92mg equivalent to estradiol 3.79 mg (50 µg/24h) excipient: acrylates copolymer ethyl oleate glyceryl monolaurate isopropyl myristate - for short-term treatment of complaints associated with the menopause and post-menopause, including signs and symptoms of oestrogen deficiency, whether naturally or surgically induced. oestrogen replacement therapy in women with an intact uterus should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals. prevention of postmenopausal osteoporosis.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

bayer new zealand limited - estradiol hemihydrate 5.88mg equivalent to estradiol 5.69 mg (75µg/24h) - transdermal patch - 75 mcg/24h - active: estradiol hemihydrate 5.88mg equivalent to estradiol 5.69 mg (75µg/24h) excipient: acrylates copolymer ethyl oleate glyceryl monolaurate isopropyl myristate - for short-term treatment of complaints associated with the menopause and post-menopause, including signs and symptoms of oestrogen deficiency, whether naturally or surgically induced. oestrogen replacement therapy in women with an intact uterus should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals. prevention of postmenopausal osteoporosis.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

bayer new zealand limited - acarbose 100mg - tablet - 100 mg - active: acarbose 100mg excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose - glucobay is indicated for the additional treatment of insulin dependant and non-insulin dependant diabetes mellitus in association with diet.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

bayer new zealand limited - acarbose 50mg - tablet - 50 mg - active: acarbose 50mg excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose - glucobay is indicated for the additional treatment of insulin dependant and non-insulin dependant diabetes mellitus in association with diet.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

bayer new zealand limited - iloprost trometamol 134 µg/ml equivalent to 100 µg iloprost/ml;  ;   - solution for infusion - 50 mcg/0.5ml - active: iloprost trometamol 134 µg/ml equivalent to 100 µg iloprost/ml     excipient: ethanol hydrochloric acid sodium chloride trometamol water for injection - treatment of patients with severe peripheral arterial occlusive disease (paod) particularly those at risk of amputation and in whom surgery or angioplasty is not possible.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

bayer new zealand limited - levonorgestrel 75mg (micronised) - subcutaneous implant - 150 mg - active: levonorgestrel 75mg (micronised) excipient: dow corning qcf-7-4910 dimethylsiloxane/methylvinylsiloxane external tubing (373-tw) polysiloxane adhesive type a - long-term contraception

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

bayer new zealand limited - vardenafil 10mg (as vardenafil hydrochloride trihydrate 11.852mg) - film coated tablet - 10 mg - active: vardenafil 10mg (as vardenafil hydrochloride trihydrate 11.852mg) excipient: colloidal silicon dioxide crospovidone hypromellose iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose titanium dioxide